Study of Potential for Drug Interactions Mediated by CYP3A4 Inhibition With Aramchol in Healthy Volunteers
Status:
Completed
Trial end date:
2019-02-02
Target enrollment:
Participant gender:
Summary
The trial is an open-label, 2-period, single-sequence assessment of CYP3A4 inhibition by
aramchol using the probe substrates midazolam and atorvastatin to assess CYP3A4 activity.
Phase:
Phase 1
Details
Lead Sponsor:
Galmed Pharmaceuticals Ltd
Collaborators:
Alderley Analytical Analyst Research Laboratories Analyst Research Laboratories Ltd. Diamond Pharma Services Regulatory Affairs Consultancy Diamond PV Services Ltd Hammersmith Medicines Research Hammersmith Medicines Research (HMR)